Related Experiment Video
Updated: May 9, 2026

Laboratory Estimation of Net Trophic Transfer Efficiencies of PCB Congeners to Lake Trout (Salvelinus namaycush) from Its Prey
Published on: August 29, 2014
Identification and dose dependency of ibuprofen biliary metabolites in rainbow trout
Jenny-Maria Brozinski1, Marja Lahti, Aimo Oikari
1Åbo Akademi University, Laboratory of Organic Chemistry, Biskopsgatan 8, FI-20500 Åbo/Turku, Finland.
Abstract:
The biotransformation of the anti-inflammatory drug ibuprofen (IBF) was studied by exposing rainbow trout (Oncorhynchus mykiss) to IBF via intraperitoneal (i.p.) injection, and via water at four (0.17, 1.9, 13 and 145 μg L(-1)) exposure levels for 4d. Following exposure, the bile was collected and analyzed by LC-MS/MS methods. The identification of the formed metabolites in i.p. injected fish bile was based on the exact mass determinations by a time-of-flight mass analyzer (Q-TOF-MS) and on the studies of fragments and fragmentation patterns of precursor ions by ion trap mass analyzer (IT-MS). In addition to unmetabolized IBF, several phase I and phase II metabolites were found in the bile. The main metabolites were acyl glucuronides and taurine conjugates of IBF and of hydroxylated IBFs. The bioconcentration factors (BCFbile), defined as the ratio of the sum of IBF and its metabolites in fish bile to the concentration of IBF in water, was determined following enzymatic deconjugation and was found to range from 14000 to 49000. The highest BCFbile was found at the lowest exposure concentration (0.17 μg L(-1)). The results show that rainbow trout has a high capacity for biotransformation of IBF, and the exposure of fish to sub μg L(-1) concentrations of IBF can be determined by the analyses of the biliary metabolites of the compound.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Clearance: Role of Transporters
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacokinetics in Pediatric Patients: Drug Metabolism

